📰 Planegg News
Page 10 - Planegg News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Planegg. Real-time updates on events, politics, business and more.
February 15, 2024
EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...
February 15, 2024
EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...
February 15, 2024
EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...
February 9, 2024
EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...
February 8, 2024
EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...
February 7, 2024
EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...
February 6, 2024
Reuters first reported on Monday that Switzerland-based Novartis was in advanced talks to acquire MorphoSys, leading to the German biotech firm's shares surging more than 40%. The Swiss group will offer shareholders 68.00 euros per share in cash and take MorphoSys private after the deal, which is contingent on certain conditions, including a minimum acceptance threshold of 65% of MorphoSys' share capital and regulatory clearances, the companies said.
February 6, 2024
Tafasitamab sold to IncyteNovartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cashShareholders benefit from attractive premium of 94 percent to the one-month volume weighted average price before January 25, 2024Novartis provides ample resources to maximize...
February 6, 2024
Drug maker Novartis is in advanced talks to acquire MorphoSys, a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two people familiar with the matter said on Monday.
February 6, 2024
EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...